Tosedostat (CHR-2797)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 16:17, 4 April 2013 by Jwarner (talk | contribs) (→‎Phase II)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Preliminary Results

Phase II

Jorge Cortes, Eric Feldman, Karen Yee, David Rizzieri, Anjali S Advani, Anthony Charman, Richard Spruyt, Martin Toal, Hagop Kantarjian, Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study, The Lancet Oncology, Volume 14, Issue 4, April 2013, Pages 354-362, ISSN 1470-2045, 10.1016/S1470-2045(13)70037-8. link to article

Retrieved from "https://hemonc.org/w/index.php?title=Tosedostat_(CHR-2797)&oldid=2706"